Comparison of the Clinical Efficacy of Ampicillin/Sulbactam and Cefoperazone/Sulbactam Against Multidrug Resistant Acinetobacter Baumannii Infections in Critically Ill Patients
Recruiting
N/A
Interventional Study
Acinetobacter Baumannii Infection
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 21 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 50 (estimated)
- Sponsor
- Cairo University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
To compare the clinical effectiveness of two different sulbactam-based regimens (ampicillin-sulbactam versus cefoperazone-sulbactam) in the treatment of Acinetobacter baumannii infections in critically ill patients.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Inclusion criteria:
1. Age ≥21 years old.
2. Patient with signs and symptoms of sepsis.
3. positive culture Carbapenem-resistant Acinetobacter baumannii (CRAB).
Exclusion Criteria:
* Exclusion criteria:
1. Empirical sulbactam-based therapy against Gram-negative bac…
Contacts